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Background and aims: Protease activated receptors (PARs) have been postulated to play a role during
intestinal inflammation. The presence and role played by PAR4 in gastrointestinal functions have not been
fully clarified. The aims of this study were: (i) to examine expression of PAR4 in rat proximal colon; (ii) to
determine the mechanical effects induced by PAR4 activation in longitudinal muscle; and (iii) to
characterise the underlying mechanisms.
Methods: PAR4 expression was determined by reverse transcription-polymerase chain reaction (RT-PCR)
and immunohistochemistry. Mechanical activity was recorded as changes in isometric tension.
Results: A PCR product corresponding to the predicted size of the PAR4 signal was amplified from RNA
prepared from the colon of rats, showing the presence of PAR4 in those tissues. Immunohistochemistry
revealed that PAR4 protein was expressed on epithelial surfaces and submucosa. PAR4 activating peptides,
GYPGKF-NH2 and AYPGKG-NH2, produced concentration dependent contractile effects on longitudinal
muscle. Tetrodotoxin (TTX) or atropine significantly reduced the contractile responses to AYPGKG-NH2,
and atropine after TTX did not cause any further reduction. NK1 receptor antagonist, SR140333, or NK2
receptor antagonist, SR48968, alone or in combination, produced a reduction in PAR4 induced contractile
effect, and when coadministered with TTX abolished it. Capsaicin markedly reduced the contractions
evoked by AYPGKG-NH2.
Conclusions: The present results suggest that PAR4 is functionally expressed in rat colon and its activation
induces contraction of the longitudinal muscle both through TTX sensitive release of acetylcholine and
release of tachykinins, probably from sensory nerves. These actions may contribute to motility disturbances
during intestinal trauma and inflammation.
I
n addition to their established proteolytic roles, proteases
such as trypsin, thrombin, or cathepsin G may also act as
cell signalling molecules via protease activated receptors
(PARs). This family of seven transmembrane G protein
coupled receptors currently includes four receptor subtypes
(PAR1, PAR2, PAR3, PAR4). PAR1, PAR3, and PAR4, but not
PAR2, are activated by thrombin, whereas trypsin can activate
PAR2 and PAR4.
1 2 PAR4 can also be activated by the
neutrophil granule protease cathepsin G.3 Activation of
PARs is initiated by proteolytic cleavage of their extracellular
N terminal domain resulting in the unmasking of an
extracellular N terminal sequence that acts as a tethered
receptor activating ligand. PAR1, PAR2, and PAR4 can also be
activated by exogenously applied short synthetic peptides,
based on the sequences of their tethered ligands.
Numerous studies have been performed to clarify the role
of PARs in the physiology and pathophysiology of the
gastrointestinal tract as these tissues, more than others, are
exposed to proteinases and PARs are highly expressed
throughout the gastrointestinal tract.4 However, most of the
studies concerned the functions of PAR1 and PAR2. PAR1 and
PAR2 most likely play a role during inflammation, allergy,
and/or haemorrhage where thrombin and/or mast cell
tryptase become available as endogenous agonists. PAR2
appears to be involved in exocrine secretion5 6 and in
intestinal ion transport.7 PAR1 and PAR2 modulate smooth
muscle motility8 and their activation can induce relaxant,
contractile, or biphasic responses.9–20 Although northern blot
analysis has shown that mRNA for PAR4 is present in human
small and large intestine,21 the cell types that express PAR4
are still unknown and the physiological role played by PAR4
in the gastrointestinal tract has to be yet fully elucidated.
Hollenberg and colleagues12 have reported contractile effects
on the longitudinal muscle of rat stomach due to activation of
PAR4 by the receptor activating peptide, GYPGQV-NH2, and
lack of cross reactivity with PAR1 and PAR2. In addition, in
rat oesophageal muscularis mucosae22 and isolated airways,23
PAR4 induces relaxation, a function opposed to PAR1. In
contrast, PAR4 appears to mimic the actions of PAR1 in the
murine airway smooth muscle.24
The present study was designed to investigate whether
PAR4 is present in rat colon and if it affects gut motor
functions. The purposes were to: (i) examine expression of
PAR4 in rat proximal colon; (ii) determine the mechanical
effects induced by PAR4 activation in longitudinal smooth
muscle; and (iii) characterise the underlying mechanisms.
Specifically, the possible involvement of neurogenic mechan-
isms and the relative contribution of different neurotrans-
mitters were analysed.
METHODS
Animals
Male Wistar rats weighing 250–300 g were obtained from
Morini (Italy) and from Charles River Laboratories (Quebec,
Canada). All animals were housed in temperature controlled
rooms and had free access to food and water. Local animal
care committees approved all experimental protocols. Rats
were sacrificed by cervical dislocation, and tissues were
immediately removed for analysis.
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Abbreviations: PARs, protease activated receptors; PBS, phosphate
buffer saline; TTX, tetrodotoxin; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; EC50, half maximal contractile concentration; RT-PCR,
reverse transcription-polymerase chain reaction
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RT-PCR
For PAR4 reverse transcription-polymerase chain reaction
(RT-PCR), total RNA from rat colonic tissues was isolated
using the Trizol method (Gibco, Canada). RNA (2 mg) was
reverse transcribed and DNA was amplified according to the
following cycle conditions: dissociation of nucleic strands at
94 C˚ for one minute, annealing at 55 C˚ for 30 seconds, and
extension for one minute at 72 C˚. The primer sequences for
rat PAR4 were 59-GGA AGT CTT GAG AGA AAG GCA A and
39-GAA CCA AGA GGC ATC ACC TAT C, and for glycer-
aldehyde-3-phosphate dehydrogenase (GADPH) 59-CGG AGT
CAA CGG ATT TGG TCG TAT and 39-AGC CTT CTC CAT GGT
GGT GAA GAC. Twenty seven cycles were performed for
PAR4 and 23 cycles for GADPH. PCR products were then
separated on a 1% agarose gel with ethidium bromide and the
gel was scanned under UV light.
Immunohistochemistry
Rat colon tissues were harvested and fixed in Zamboni’s
buffer overnight. Tissues were then washed three times in
phosphate buffer saline (PBS) and placed in 20% sucrose
with PBS. Tissues were embedded in OCT and frozen sections
(10 mm) were placed on ‘‘superfrost plus’’ slides. Tissue
sections were washed with PBS alone and then incubated for
one hour at room temperature with PBS containing 10%
donkey serum. Sections were then incubated with primary
antibody (affinity purified goat polyclonal anti-PAR4 anti-
body; Santa Cruz Biotechnology, California, USA; 1/100
dilution) in PBS with 10% donkey serum overnight at 4 C˚.
In control experiments, the anti-PAR4 antibody was pre-
incubated (for 24–48 hours at 4 C˚ with 1 or 10 mM of) with
the blocking peptide used for immunisation (peptide map-
ping the C terminal domain of mouse PAR4; Santa Cruz
Biotechnology). Slides were washed in PBS and incubated
with secondary antibody (Cy3 conjugated AffiniPure donkey
antigoat, 1/500 dilution in PBS plus 1.5% donkey serum) for
one hour at room temperature. Tissue sections were then
covered with Fluorsave reagent and examined using a
Olympus IX50/FLA fluorescent microscope equipped with a
coolsnap-fx camera.
Mechanical recording
Rat colon was removed distally to the caecum. The colonic
lumen was cleaned with Krebs solution and segments of
approximately 2 cm in length were cut. The preparation was
then placed in a continuously perfused organ bath containing
5 ml of gassed (95% O2 and 5% CO2) and heated (37 C˚) Krebs
solution with the following composition (mM): NaCl 119;
KCl 4.5; MgSO4 2.5; NaHCO3 25; KH2PO4 1.2; CaCl2 2.5; and
glucose 11.1. Preparations were then tied with silk thread to
an isometric force transducer (DY2; Ugo Basile, Comerio,
Varese, Italy) for recording of isometric tension of the longi-
tudinal muscle on an ink writer recorder (Gemini; Ugo
Basile). Segments were allowed to equilibrate for at least
30 minutes under a 1 g load before starting the experiment.
Experimental protocol
After the equilibration period, the preparation was chal-
lenged with carbachol at 10 mM which, in preliminary
experiments, was demonstrated to induce a maximal effect.
Then, responses of the preparations to cumulative concentra-
tions of GYPGKF-NH2, the murine synthetic PAR4 activating
peptide, AYPGKG-NH2, which is reported to be a stronger
agonist for PAR4,
25 or YAPGKG-NH2, the inactive control
peptide, were examined. The peptides were added into the
bath in volumes of 50 ml after switching off the perfusion to
give the concentrations indicated. Each concentration was
left in contact with the tissue for two minutes. In preliminary
experiments, in order to assess the reproducibility of the
responses, we found that concentration related responses
obtained with the first concentration-response curve were
not significantly different from the second curve.
The response to PAR4 activation with AYPGKG-NH2 was
assessed in the absence and presence of the following
inhibitors/antagonists: tetrodotoxin (TTX 1 mM), a Na+
channel blocker; atropine (1 mM), an antagonist of choliner-
gic muscarinic receptors; SR140333, a selective antagonist of
NK1 receptors (1 mM); SR48968, a selective antagonist of NK2
receptors (1 mM); and capsaicin at a concentration of 10 mM,
which is reported to cause depletion of tachykinins from
sensory nerve fibres.26 27 Some antagonists were coadminis-
tered to clarify whether the effectors represented different
steps of the same pathway. For each drug, the concentration
used was known to be effective in our preparation.28 29 The
antagonists were added to the perfusing solution at least 30
minutes before testing the PAR activating peptides, except
capsaicin. To prove that TTX treatment was effective, the
preparation was stimulated through a pair of platinum ring
electrodes.
Data analysis and statistics
Because of spontaneous phasic contractions of the tissues,
the contractile response of longitudinal muscle was defined
as change in resting tone (the bottom level of the tension
oscillations), and was expressed as a percentage of contrac-
tion caused by 10 mM carbachol. All data are expressed as
means (SEM) where n indicates the number of animals from
which intestinal segments were taken. The half maximal
contractile concentration (EC50) was calculated from indivi-
dual experiments by non-linear regression. Differences in
peptide induced responses in the absence (control) and
presence of inhibitors were analysed by the Student’s t test or
analysis of variance (ANOVA) and Bonferroni’ correction,
when required. A probability value of less than 0.05 was
regarded as significant.
Drugs
The following drugs were used: carbamylcholine chloride
(carbachol), capsaicin, tetrodotoxin (TTX) (Sigma, Chemical
Corp, St Louis, Missouri, USA), ((S)-N-methyl-N [4-(4-
acetyl-amino-4-phenylpiperi-dino)-2-(3, 4-dichloro-phenyl)-
butyl]benzamide (SR48968), (S)-1-[2-[3-(3, 4-dichlorphe-
nyl)-1 (3-isopropoxy-phenylacetyl) piperidin-3yl] ethyl]-4-
phenyl-1 azaniabicyclo [2.2.2] octane chloride (SR140333) (a
kind gift from Sanofi Recherche, Montpellier Ce´dex, France),
[Sar9, Met(O2)
11]-SP, [b-Ala8]-NKA(4–10) (Calbiochem-
Novabiochem AG, Laufelfingen, Switzerland). All drugs were
dissolved in distilled water, except for the following: SR48968
and SR140333 dissolved in DMSO, capsaicin dissolved in
absolute ethanol, [Sar9, Met(O2)
11]-SP dissolved in diluted
acetic acid, and [b-Ala8]-NKA(4–10) dissolved in diluted
ammonia. Working solutions were prepared fresh on the day
of the experiment by diluting the stock solutions. Control
experiments using the different solvents alone showed that
none had effects on the tissue responses studied.
GYPGKF-NH2, AYPGKG-NH2, and the inactive control
peptide YAPGKF-NH2 were purchases from the Peptide
Synthesis Core Facility at the University of Calgary
(Canada), and prepared by standard solid phase synthesis
procedures.
RESULTS
PAR4 expression
A PCR product of a predicted size of 463 bp was amplified
from RNA prepared from the colon of rats (lanes 1 and 2;
fig 1), showing PAR4 presence in those tissues. In the absence
of PAR4 primer, only GAPDH amplified product (306 bp) was
detected in those tissues (lane 3; fig 1). PAR4 protein
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immunoreactivity was also observed in rat colon (fig 2). PAR4
expression was prominently localised to the mucosal surface
(colonocytes; arrowheads in fig 2A), but staining was also
observed in the submucosa (arrows in fig 2A). Staining was
abolished by preabsorption of antibody with the receptor
fragment used to raise the anti-PAR4 antibody (fig 2B).
Functional studies
Under the present experimental conditions, rat colon smooth
muscle showed spontaneous mechanical activity, consisting
in rhythmic phasic changes of isometric tension (from 1 to
2.5 g). The PAR4 activating peptides, GYPGKF-NH2 (0.01–
10 mM) and AYPGQV-NH2 (0.01–10 mM), caused a concen-
tration dependent contractile response in the longitudinal
muscle of rat colon, consisting of an increase in basal tension
with maintenance of the phasic contraction (fig 3). AYPGQV-
NH2 (EC50 = 0.08 (0.06) mM; n = 6) was more potent than
GYPGKF-NH2 (EC50 = 0.3 (0.1) mM; n = 8) but efficacy was
similar, both peptides being able to reach approximately 90%
of the contraction induced by carbachol (10 mM) at the
maximal concentration tested (fig 4). In order to verify the
specificity of the response, we applied to the preparations the
inactive control peptide YAPGQV-NH2 (0.01–10 mM) and this
had no effect (figs 3, 4).
To clarify the mechanism underlying the contractile effect
produced by PAR4 activation, we evaluated the responses
evoked by AYPGQV-NH2 in the presence of TTX. TTX (1 mM),
which per se did not modify spontaneous contractions,
significantly reduced the responses induced by the PAR4
activating peptide, but did not abolish them, indicating
partial involvement of neural mechanism (fig 5A).
As tachykinins and acetylcholine are among the major
excitatory neurotransmitters to intestinal smooth muscle, we
evaluated if these mediators could be involved in the PAR4
agonist induced contractile response. Therefore, we tested the
effects of their antagonists on responses evoked by PAR4
activation both in the absence and presence of TTX.
Pretreatment of tissues with the muscarinic antagonist
atropine (1 mM) significantly decreased the contractile
responses induced by AYPGKF-NH2 (fig 5A). Contractile
responses to 10 mM carbachol were absent in these tissues
(data not shown). It is interesting that the reduction in the
PAR4 contractile effect induced by atropine was of the same
degree as that induced by TTX; furthermore, subsequent
addition of atropine (1 mM) after TTX caused no further
reduction of the PAR4 induced contractile effect (fig 5A).
Both NK1 and NK2 receptor antagonists, SR140333 (1 mM)
and SR48968 (1 mM), respectively, reduced independently
the contractile effects induced by PAR4 activating peptide
(fig 5B). The concentration of the NK1 receptor selective
antagonist SR140333 that we used (1 mM) antagonised the
contractile response to the NK1 receptor agonist [SAR
9,
Met(O2)
11]-SP but not to the NK2 receptor agonist [b-ala
8]-
neurokinin A (4–10). The concentration of the NK2 receptor
selective antagonist SR48968 that we used (1 mM) antag-
onised the contractile response to the NK2 receptor agonist
[b-ala8]-neurokinin A (4–10) but not to the NK1 receptor
agonist [SAR9, Met(O2)
11]-SP (data not shown). The
suppressive effects of the NK1 receptor selective antagonist
SR140333 (1 mM) were additive to those induced by the NK2
receptor selective antagonist SR48968 (1 mM) (fig 5B).When
both antagonists were coadministered with TTX (1 mM), the
contractile effects evoked by PAR4 activating peptide were
abolished (fig 5B).
Lastly, pretreatment of the preparation with capsaicin
(10 mM) for 90 minutes significantly reduced the contractile
effects induced by PAR4 activating peptide (fig 6).
DISCUSSION
Possible physiological/pathophysiological roles for PAR4 in
tissues or cells other than platelets are poorly understood, in
spite of their wide distribution in varying tissues.12 21 30–32
Considering the effects of PAR4 agonists on smooth muscles,
some evidence indicates the PAR4 is not involved in
modulation of the motility of rat duodenum16 or guinea pig
gall bladder.18 However, Hollenberg and colleagues12 have
reported that PAR4 agonists induce contraction of gastric
longitudinal smooth muscle and nitric oxide dependent
GAPDH
PAR4
400bp
500bp
300bp
1 2 3
Figure 1 Detection of protease activated receptor 4 (PAR4) in rat colon
by reverse transcription-polymerase chain reaction. Lanes 1 and 2,
colon tissues where PAR4 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) primers were amplified; a specific 463 bp
fragment corresponds to PAR4 while GAPDH showed an expected
amplified fragment of 306 bp. Lane 3 shows omission of PAR4 primer.
A B
m m
sm smcm
Figure 2 Immunolocalisation of protease activated receptor 4 (PAR4) in rat colon. In (A), tissues were incubated with an anti-PAR4 primary antibody
and then with a Cy3 conjugated secondary antibody. The control (B) shows incubation of primary anti-PAR4 antibody with blocking peptide, followed
by Cy3 conjugated secondary antibody. m, mucosa, sm, submucosa, cm, circular muscle. Arrowheads shows colonocyte staining, arrows shows
submucosa staining. Scale bar, 10 mm.
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relaxation of vascular smooth muscle. It is not yet clear
whether PAR4 activation plays a role similar or opposite to
PAR1. In fact, PAR4 activation appears to mimic the effects of
PAR1 activation in gastric and airway smooth muscle,
12 24
whereas in the rat oesophageal muscularis mucosae, PAR4
appears to mediate relaxation, in contrast to PAR1.
22
The present study demonstrates that PAR4 is present in rat
colon and its activation evokes contraction of intestinal
longitudinal smooth muscle. Both GYPGKF-NH2, corre-
sponding to the murine PAR4 tethered ligand, and
AYPGKF-NH2, reported to be a more potent peptide analogue
for PAR4,
25 induced a concentration dependent contractile
response. The control inactive peptide YAPGKF-NH2 had no
contractile effect on longitudinal smooth muscle prepara-
tions, thus confirming the specificity of action of the two
PAR4 peptide agonists used. AYPGQV-NH2 was more potent
than GYPGKF-NH2, which is in accordance with data from
the literature.25 The effective concentration range of
GYPGKF-NH2 and AYPGQV-NH2 for induction of the
contractile responses was lower than that required for
production of contraction in other preparations.12 One
possible explanation for this observation is that in our
preparation the PAR4 activating peptides were not susceptible
to rapid protease degradation, or alternatively the high
potency of agonist may reflect greater expression of this type
2 min
1 g
0.01 0.1 1 10 0.01 0.1 1 10 0.01 0.1 1 10 CCh W
GYPGKF-NH2 (µM) AYPGKF-NH2 (µM) YAPGKF-NH2 (µM)
Figure 3 Representative recordings of the contractile effects induced by the protease activated receptor 4 (PAR4) activating peptides, GYPGKF-NH2
and AYPGKF-NH2, by the inactive control peptide, YAPGKF-NH2, and by carbachol (CCh 10 mM) on the longitudinal muscle of rat colon. Arrows
indicate application of the agonist. W, washout.
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Figure 4 Concentration-response curves for the effects evoked by the
protease activated receptor 4 (PAR4) activating peptides, GYPGKF-NH2
and AYPGKF-NH2, and the inactive control peptide, YAPGKF-NH2, on
the longitudinal muscle of rat colon. The contractile effects are expressed
as a percentage of the contraction to carbachol (CCh 10 mM). Each
value is the mean (SEM) of 4–8 experiments.
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Figure 5 (A) Effects of tetrodotoxin (TTX) and atropine, alone or in
combination, on the contractile responses evoked by protease activated
receptor 4 (PAR4) activating peptide, AYPGKF-NH2, on the longitudinal
muscle of rat colon. The contractile responses to AYPGKF-NH2 were
significantly reduced by TTX (1 mM) or atropine (1 mM). The combination
of atropine (1 mM) and TTX (1 mM) did not cause any further reduction.
(B) Effects of SR140333 and SR48968, alone, in combination, or after
treatment with TTX, on the contractile responses evoked by PAR4
activating peptide, AYPGKF-NH2, on the longitudinal muscle of rat
colon. The contractile responses to AYPGKF-NH2 were significantly
reduced by SR140333 (1 mM), an antagonist of NK1 receptors, by
SR48968 (1 mM), an antagonist of NK2 receptors, and even more by a
combination of SR48968 (1 mM) and SR140333 (1 mM). AYPGKF-NH2
did not induce any response in the presence of a combination of
SR48968 (1 mM), SR140333 (1 mM), and TTX (1 mM). The contractile
effects are expressed as a percentage of the contraction to carbachol
(CCh 10 mM). Each value is mean (SEM) of five experiments. *p,0.05
compared with control value; p.0.05 compared with TTX or atropine
alone; `p,0.05 compared with SR140333 and SR48968 alone;
1p,0.05 compared with the combination of SR140333 and SR48968.
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of receptor in the colon than in the stomach, as reported by
Xu and colleagues.21
However, the contractile effects we demonstrated for PAR4
agonists in rat colonic smooth muscle preparations suggest a
role for this receptor in motility functions of the gut. Whether
or not this role is associated with pathophysiological
circumstances may depend on the availability of endogenous
proteases in the vicinity of the receptor. Which endogenous
protease activates PAR4 in intestinal tissues remains to be
established. Both thrombin and trypsin have been reported to
activate PAR4.
21 In a previous study, we demonstrated that
thrombin and trypsin induced contractile effects in rat
colonic longitudinal muscle preparations, showing biphasic
responses: relaxation followed by contraction for the highest
concentrations.19 These effects were mimicked by PAR1 and
PAR2 activating peptides, suggesting that thrombin and
trypsin could be responsible for endogenous activation of
PAR1 and PAR2, respectively. However, the present results
highlight PAR4 as another potential effector of both thrombin
and trypsin. The similar effects of PAR1, PAR2, and PAR4
could make redundant the effects of thrombin and trypsin in
rat intestinal longitudinal muscle as was suggested for
platelets and smooth muscles from gastric, vascular, and
airway tissues.12 24 30 31 33 Recently, the neutrophil granule
protease cathepsin G3 has been found to stimulate PAR4. This
adds cathepsin G to the list of potential endogenous
activators of PAR4 in intestinal tissues. Moreover, it links
PAR4 activation in those tissues to the presence of granulo-
cytes, suggesting that inflammatory pathophysiological cir-
cumstances, such as inflammatory bowel diseases, may be
associated with PAR4 activation.
We examined the mechanism by which PAR4 activation
induces contractile effects in rat colonic longitudinal muscle
by treating the preparation with TTX, a neuronal conduction
blocker, to assess the role of neurotransmission in the evoked
effect. The finding that the contractile responses to PAR4
activating peptides were antagonised, although not comple-
tely, by TTX, suggests that a neurogenic component is
involved in the PAR4 agonist evoked effect. Previous studies
have reported that PAR1 and PAR2 are expressed by a large
proportion of neurones of the myenteric plexus of the guinea
pig intestine34 and PAR2 receptors are expressed on choliner-
gic nerves in porcine ileum.35 However, information on the
cellular localisation of PAR4 in intestinal tissue is lacking. In
mouse, PAR4 expression on peripheral nerves of bladder has
been shown.36 We observed immunostainning for PAR4 in
submucosal structures which could be submucosal neurones
(fig 2A), but double labelling with a neuronal marker would
be necessary to ascertain that PAR4 is expressed on neurones
in the rat colon. We have evaluated if acetylcholine or
tachykinins could be responsible for the PAR4 neurally
mediated effect because these chemical mediators are
considered the major excitatory neurotransmitters of intest-
inal smooth muscle. Atropine reduced the contractile
response to PAR4 activation to the same extent as TTX but
failed to decrease it further after TTX treatment. This
indicates that PAR4 activation can induce acetylcholine
release through an action potential dependent neural
mechanism. In addition, NK1 and NK2 receptor antagonists,
when administered separately or in combination, reduced
contraction due to PAR4 activation, suggesting involvement
of these receptors in the effects evoked by AYPGKF-NH2. The
presence of these receptors, which mediate contraction in the
rat colon, has been demonstrated previously by histochemical
and functional studies.26 37 38 On the other hand, the action of
both SR140333 and SR48968 has to be considered as
specifically linked to occupancy of NK1 or NK2 receptors,
respectively, as these drugs antagonised exclusively contrac-
tion induced by selective agonists of the respective receptors.
Because the suppressive effects of NK1 and NK2 receptor
antagonists were additive to the effect of TTX, it could be
hypothesised that PAR4 activation can induce tachykinin
release without the contribution of propagated action
potential (TTX resistant release). In fact, TTX may not inhibit
release of neurotransmitters following direct stimulation of
receptors present in nerve terminals. Therefore, we hypothe-
sise that prejunctional PAR4 may directly induce the release of
tachykinins, which are mostly released by neurones in the gut.26
In addition, capsaicin significantly reduced the response
induced by PAR4 activating peptide. Although capsaicin can
cause different effects, such as VR1 receptor desensitisation
or blockade of voltage gated calcium channels, it is likely that
the effect of 10 mM capsaicin for 90 minutes can be
attributed to an inhibitory effect on the release of biologically
active substances, such as tachykinins, by sensory nerve
fibres.26 27 Depletion of tachykinins from sensory nerves could
account for the reduction in contractile effect to PAR4
activation. It has been reported that PAR2 activation
stimulates the release of substance P from terminals of
capsaicin sensitive primary sensory neurones, thus causing
neurogenic inflammatory responses in peripheral tissue.39
Interestingly, a similar system has also been described for
trypsin induced contraction of the guinea pig bronchus, with
release of tachykinins from sensory nerves being responsible
for the final contractile response.40 41 In addition, our recent
data have suggested that PAR1 and PAR2 activation can
induce neural tachykinin release.29
In conclusion, this study has demonstrated for the first
time that PAR4 is functionally expressed in rat colon. It can
mediate a contractile response of longitudinal muscle
through TTX sensitive release of acetylcholine and through
action potential independent release of tachykinins, probably
from sensory nerves. This mechanism of action may support a
proinflammatory role for PAR4, which could contribute to
motility disturbances observed during intestinal trauma and
inflammation.
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